|Fastest Growing Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The Zika virus testing market is expected to register a CAGR of 5.5% during the forecast period, 2022-2027.
Covid-19 had a significant impact on the zika virus testing market. Since the beginning of 2020, the Covid-19 pandemic has changed the healthcare system as well as affected the lifestyle of the population worldwide. The spread of infectious diseases increased with the rising prevalence of coronavirus, and hence the demand for testing to diagnose the zika virus also increased during the pandemic. A study published in October 2021 titled “Dual burden of Zika and COVID-19 in India: challenges, opportunities and recommendations” showed that Zika infection resembles closely COVID-19 and other arboviral infections and stated that there is a huge risk of Zika Virus Disease spread in India, which is especially dangerous in the backdrop of this Covid-19 pandemic. Thus, public health measures, vector control, and early diagnosis, especially in the case of pregnant women, are suggested during the pandemic in India to control the spread of the disease. Hence, the similar nature of infection of both the Covid-19 and Zika virus led to an increasing zika virus testing for diagnosis purposes globally, which is predicted to have a positive impact on the overall studied market.
Factors such as the increasing prevalence of zika virus infection and technological advancements in zika virus testing are the major factors driving the growth of the market studied. Zika virus (ZIKV) infection has been known to be endemic in Africa and Southeast Asia. The consequent viral spread over the Pacific region led to an outbreak in the developed and emerging countries. In addition, there have been major outbreaks of Zika virus infection in Asia-Pacific (particularly India) and South American countries. Also, the World Health Organization (WHO) data updated in February 2022, stated that Zika transmission persists in several countries but is most common at low levels throughout 2018 to the present. Thus, the rising prevalence of Zika virus infection is one of the primary factors driving the growth of the market studied over the forecast period.
The other prominent drivers of the market studied are increasing research and development by biopharmaceutical companies and technological advancements in diagnostic tests. Adding to that, governments worldwide are focusing more on initiatives to fight zika virus transmission is driving the studied market growth. For instance, in May 2022, the government of Uttar Pradesh (India) launched the ‘Zero Mission’ 'Zero to eradicate vector-borne diseases such as Japanese encephalitis, dengue, malaria, typhoid, pneumonia, and Zika virus. Thus, the rising prevalence of Zika virus infection worldwide coupled with government initiatives are among the primary factors driving the growth of the market studied over the forecast period.
Therefore, the insights mentioned above are expected to propel the zika virus testing market growth globally in the future. However, the excessive cost of testing kits is predicted to hinder market growth in the future.
Scope of the Report
As per the scope of the report, a Zika virus test is usually a blood test or a urine test, where the physician or other healthcare provider will take a blood sample from a vein in the patient’s arm using a small needle. The zika virus testing market is segmented by Test Type (Molecular Test and Serologic Test), End-User (Hospital/Clinic, Diagnostics Laboratory, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for the above segments.
|By Test Type|
|By End User|
Key Market Trends
Serologic Test Segment is Expected to Show Better Growth Over the Forecast Years
Nucleic acid amplification test (NAAT) is a generic term referring to all molecular tests used to detect viral genomic material. The NAAT assays are the preferred method of diagnosis because they can provide confirmed evidence of infection. The increasing demand for molecular tests for zika virus testing has been increasing recently. Hence the molecular test segment is anticipated to witness growth over the forecast period.
The increasing research and development in the molecular testing segment are bolstering the growth of the segment. For instance, in March 2022, an international team of researchers headed by experts from the University of Toronto revealed results for one of the first field trials for a synthetic biology-based diagnostic using patient samples. This study was conducted on-site in Latin America and reveals the potential for cell-free synthetic biology tools and companion hardware for providing rapid, decentralized, and low-cost patient testing for infectious diseases like the Zika virus. The study results published in Nature Biomedical Engineering show that the novel diagnostic platform has analytical specificity and sensitivity, which is equivalent to the United States Centre for Disease Control PCR test for Zika and has a diagnostic accuracy of 98.5% with 268 patients samples collected in Recife, Brazil. The platform is also programmable and can be similarly applied to detect any pathogen sequence. Also, the researchers state that on the molecular side, the cell-free tests can be freeze-dried, allowing for distribution without refrigeration. All the molecular components of the test are independent of the PCR-supply chain. Thus, the increasing research on molecular testing and its efficacy is bolstering the segment growth.
The recent developments are also increasing in the segment and contributing to the segment growth. For instance, in November 2021, the India Molecular Diagnostics and Research Laboratory (MDRL) of the Government Institute of Medical Sciences (GIMS) in Greater Noida, India, started conducting tests for the zika virus. In addition, in September 2021, Roche signed a definitive share purchase agreement to acquire 100% of the shares of TIB Molbiol Group to enhance its molecular diagnostic solutions portfolio. Thus, the continuous development in the segment is expected to drive the segment growth.
Therefore, the molecular test segment is anticipated to grow over the forecast period, positively impacting the overall growth of the studied market.
To understand key trends, Download Sample Report
Asia Pacific is Expected to Dominate the Market in the Forecast Period
With the increasing prevalence of Zika virus (ZIKV) in the countries across Asia-pacific, especially the spread of Zika virus in India, the region is anticipated to dominate the market over the forecast period.
The prevalence and incidence of the zika virus in India are anticipated to drive the demand for zika virus testing in the country. The World Health Organization (WHO) data updated in October 2021 shows that on July 8, 2021, a ZIKV infection was laboratory-confirmed in a resident of Kerala, India. This represented the first Zika virus disease case ever reported from Kerala. Again, on July 31, 2021, Maharashtra state also reported its first Zika laboratory-confirmed case from Belsar village in Pune, India. In addition, Indian health authorities reported a total of 152 Zika virus cases in Uttar Pradesh as of December 5, 2021. The outbreak began in October and represented the first major outbreak identified in the state.
Moreover, as per the data provided by the Union Minister of Health and Family Welfare, 237 Zika virus cases were reported in December 2021, across India. Hence, the increasing prevalence of the zika virus has created an emergence of zika virus testing in the country and thereby driving the growth of the studied market in the country.
Furthermore, the article titled “Zika Virus in India and The Global Case for New Prevention and Control Strategies” in October 2021 stated that, after the Zika virus detection was confirmed in 2017, the government of India has taken steps to implement effective Zika control programs, including adding more laboratories for conducting Zika surveillance and currently more than 25 laboratories nationwide are equipped for Zika testing. These initiative steps taken by the government are expected to drive the demand for zika virus testing in India, driving the overall market growth.
Apart from India, serological evidence of widespread Zika Virus has been found in some other countries in Asia-Pacific. An article titled “Serological Evidence of Widespread Zika Transmission across the Philippines” published in July 2021 stated that when and 997 serum samples were randomly collected from dengue patients and tested for ZIKV, and evidence of widespread ZIKV exposure across the Philippines was found. The above-mentioned study also suggested for zika virus testing across the country is needed to find the ZIKV infection risk factor. Thus, the spread of the zika virus across countries in Asia-pacific is expected to drive the studied market growth in the region.
Therefore, owing to the factors mentioned above, the zika virus testing market is anticipated to see growth over the forecast period in the Asia-Pacific region.
To understand geography trends, Download Sample Report
The market is competitive due to the presence of major players in the global market. In the current scenario, the number of product launches, collaborations, and other strategies by the market players is increasing and it is fueling the global zika virus testing market. Abbott, F. Hoffmann-La Roche Ltd, DiaSorin (Luminex Corporation), Quest Diagnostics, and Siemens Healthcare GmbH are some of the major players, among others.
DiaSorin (Luminex Corporation)
F. Hoffmann-La Roche Ltd
Siemens Healthcare GmbH
- In March 2022, the World Health Organization launched the Global Arbovirus Initiative. Arthropod-Borne viruses (Arboviruses) are Dengue, Yellow fever, Chikungunya, and Zika viruses which are current public health threats globally. This integrated initiative will build a coalition of key partners to strengthen the coordination, communication, capacity-building, research, preparedness, and response necessary to mitigate the growing risk of epidemics due to these diseases.
- In February 2022, in view of repeated outbreaks of highly infectious pathogens like Zika, Avian influenza, and Covid-19, the Indian Council of Medical Research (ICMR) and Klenzaids collaboratively launched India's first Mobile BSL-3 enhanced laboratory in Maharashtra, India. The laboratory was built at the cost of about INR 25 crores. The BSL-3 enhanced laboratory is a self-sufficient unit, which has every system and equipment essential for full standalone operation.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Zika Virus Infection
4.2.2 Increasing R&D by Biopharmaceutical Companies
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Excessive Cost of Testing Kits
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Test Type
5.1.1 Molecular Test
5.1.2 Serologic Test
5.2 By End User
5.2.2 Diagnostics Laboratory
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.2 altona Diagnostics GmbH
6.1.3 Chembio Diagnostics, Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.7 DiaSorin (Luminex Corporation)
6.1.8 Novacyt Group
6.1.9 Quest Diagnostics
6.1.10 Siemens Healthcare GmbH
6.1.11 LGC Limited (SeraCare Life Sciences)
6.1.12 Co-Diagnostics, Inc.
6.1.13 Mediven (Medical Innovation Ventures )
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Frequently Asked Questions
What is the study period of this market?
The Global Zika Virus Testing Market market is studied from 2019 - 2027.
What is the growth rate of Global Zika Virus Testing Market?
The Global Zika Virus Testing Market is growing at a CAGR of 5.5% over the next 5 years.
Which region has highest growth rate in Global Zika Virus Testing Market?
North America is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Zika Virus Testing Market?
Asia-Pacific holds highest share in 2021.
Who are the key players in Global Zika Virus Testing Market?
Abbott, DiaSorin (Luminex Corporation), F. Hoffmann-La Roche Ltd, Quest Diagnostics, Siemens Healthcare GmbH are the major companies operating in Global Zika Virus Testing Market.